In November 2020, within the period used to define the COVID-19 cohort for this analysis, the European Medicines Agency approved nivolumab plus ipilimumab with two cycles of chemotherapy for 1L treatment of mNSCLC, in adults whose tumours have no sensitising EGFR mutation or ALK translocations [47]. Here, ALK is linked to neoplasm.